U.S. biotech pharmaceutical firm Celgene Corp said on Sunday that it had agreed to acquire Impact Biomedicines for as much as $7 billion, subject to certain milestones associated with regulatory hurdles and sales performance.
Celgene is interested in Impact Biomedicines’ fedratinib, a kinase inhibitor that has shown promise as a potential treatment for a type of blood cancer called myelofibrosis, according to a statement put out jointly by both companies.
“Myelofibrosis is a disease with high unmet medical need as the number of patients who are ineligible for or become resistant to existing therapy continues to increase,” said Nadim Ahmed, Celgene’s president of hematology and oncology.
“(Fedratinib) provides strategic options for us to build leadership in this disease.”
The deal is structured in three parts, with Celgene paying $1.1 billion in cash upfront for the San Diego-based company.
Celgene will pay an additional $1.4 billion, depending on the receipt of U.S. Food and Drug Administration milestone approvals.
Finally, Celgene will make payments depending on sales, with a maximum of $4.5 billion due if annual net sales of Impact’s treatments exceed $5 billion.
Celgene is a bio-technology company based in Summit, New Jersey, that specializes in treatments for multiple myeloma.
By Elizabeth Dilts
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).